Specific immunotherapy of experimental myasthenia gravis in vitro and in vivo: The Guided Missile strategy

Journal of Neuroimmunology

Volumn 251, Issue 1-2, 2012, Pages 25-32

  Sun, W ^a   Adams, R N ^b   Miagkov, A ^c   Lu, Y ^d   Juon, H S ^e   Drachman, D B ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Caliper Life Sciences   (United States)

^d Sirnaomics Inc   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Dendritic cells; Fas ligand; Genetic engineering; Guided Missile; Myasthenia gravis; Specific immunotherapy

Indexed keywords

CHOLINERGIC RECEPTOR; DENDRITIC CELL VACCINE; FAS LIGAND;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL ENGINEERING; CELL KILLING; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES; CELLS, CULTURED; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EPITOPES; FAS LIGAND PROTEIN; FEMALE; GENETIC ENGINEERING; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RECEPTORS, CHOLINERGIC; T-LYMPHOCYTES;

EID: 84865632815     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.06.007     Document Type: Article

References (68)

1. Ashany D., Savir A., Bhardwaj N., Elkon K.B. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. J. Immunol. 1999, 163:5303-5311.
2. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
3. Berger J.R., Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann. Neurol. 2009, 65:367-377.
4. Bohana-Kashtan O., Civin C.I. Fas ligand as a tool for immunosuppression and generation of immune tolerance. Stem Cells 2004, 22:908-924.
5. Bowles R., Patil S., Pincas H., Sealfon S. Optimized protocol for efficient transfection of dendritic cells without maturation. J. Vis. Exp. 2011, 53. (10.3791/2766).
6. Brocke S., Brautbar C., Steinman L., Abramsky O., Rothbard J., Neumann D., et al. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J. Clin. Invest. 1988, 82:1894-1900.
7. Cao H., Koehler D., Hu J. Adenoviral vectors for gene replacement therapy. Viral Immunol. 2004, 17:327-333.
8. Chen J.W., Cha Y., Yuksel K.U., Gracy R.W., August J.T. Isolation and sequencing of a cDNA clone encoding lysosomal membrane glycoprotein mouse LAMP-1. Sequence similarity to proteins bearing onco-differentiation antigens. J. Biol. Chem. 1988, 263:8754-8758.
9. Christadoss P., Dauphinee M.J. Immunotherapy for myasthenia gravis: a murine model. J. Immunol. 1986, 136:2437-2440.
10. Cole R., Ghazanfari N., Ngo S., Gervasio O., Reddel S., Phillips W. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J. Physiol. 2010, 588:3217-3229.
11. Conti-Fine B.M., Navaneetham D., Karachunski P.I., Raju R., Diethelm-Okita B., Okita D., et al. T cell recognition of the acetylcholine receptor in myasthenia gravis. Ann. N. Y. Acad. Sci. 1998, 841:283-308.
12. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 1994, 330:1797-1810.
13. Drachman D.B. Therapy of myasthenia gravis. Neuromuscular Junction Disorders; Handbook of Neurology 2008, vol. 3rd Series:251-270. Elsevier, London. A.G. Engel (Ed.).
14. Drachman D.B., Adams R.N., Stanley E.F., Pestronk A. Mechanisms of acetylcholine receptor loss in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 1980, 43:601-610.
15. Drappa J., Brot N., Elkon K.B. The Fas protein is expressed at high levels on CD4+CD8+ thymocytes and activated mature lymphocytes in normal mice but not in the lupus-prone strain, MRL lpr/lpr. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10340-10344.
16. Ehrhardt A., Kay M. Gutted adenovirus: a rising star on the horizon?. Gene Ther. 2005, 12:1540-1541.
17. Eldefrawi M.E., Eldefrawi A.T. Purification and molecular properties of the acetylcholine receptor from Torpedo electroplax. Arch. Biochem. Biophys. 1973, 159:362-373.
18. Engel A., Sahashi K., Lambert E., Howard F. The ultrastructural localization of the acetylcholine receptor, immunoglobulin G and the third and ninth complement components at the motor endplate and their implications for the pathogenesis of myasthenia gravis. Current Topics in Nerve and Muscle Research 1979, 111-122. Excerpta Medica, Montreal, Canada. A. Aguayo, G Karpati (Eds.).
19. Fambrough D.M., Drachman D.B., Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973, 182:293-295.
20. Green M., Loewenstein P.M. Human adenoviruses: propagation, purification, quantification, and storage. Curr. Protoc. Microbiol. 2006, 14C.1.1-14C.1.19.
21. Guarnieri F.G., Arterburn L.M., Penno M.B., Cha Y., August J.T. The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1. J. Biol. Chem. 1993, 268:1941-1946.
22. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 2002, 20:621-667.
23. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 2001, 7:365-368.
24. Hohlfeld R., Toyka K.V., Miner L.L., Walgrave S.L., Conti-Tronconi B.M. Amphipathic segment of the nicotinic receptor alpha subunit contains epitopes recognized by T lymphocytes in myasthenia gravis. J. Clin. Invest. 1988, 81:657-660.
25. Hoves S., Krause S., Halbritter D., Zhang H.-G., Mountz J., Scholmerich J., et al. Mature, but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from fas-mediated apoptosis and can be used as killer APC. J. Immunol. 2003, 170:5406-5413.
26. Hoves S., Krause S., Herfarth H., Halbritter D., Zhang H.-G., Mountz J., et al. Elimination of activated but not resting primary human CD4+ and CD8+ cells by Fas ligand (FasL/CD95L)-expressing killer-dendritic cells. Immunobiology 2004, 208:463-475.
27. Inaba K., Swiggard W.J., Steinman R.M., Romani N., Schuler G., Brinster C. Isolation of dendritic cells. Curr. Protoc. Immunol. 2009, 86:3.7.1-3.7.19.
28. Jones H., Klein N, Dixon GL Human dendritic cell culture and bacterial infection. Methods Mol. Biol. 2012, 799:217-235.
29. Jung C., Stoeckle C., Wiesmuller K.H., Laub R., Emmrich F., Jung G., et al. Complementary strategies to elucidate T helper cell epitopes in myasthenia gravis. J. Neuroimmunol. 2008, 201-202:41-49.
30. Kao I., Drachman D.B. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 1977, 196:527-529.
31. Kaul R., Shenoy M., Goluszko E., Christadoss P. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 1994, 152:3152-3157.
32. Lenardo M., Chan K.M., Hornung F., McFarland H., Siegel R., Wang J., et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 1999, 17:221-253.
33. Lennon V.A., Lindstrom J.M., Seybold M.E. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann. N. Y. Acad. Sci. 1976, 274:283-289.
34. Lindstrom J.M. Experimental autoimmune myasthenia gravis: induction and treatment. Myasthenia Gravis and Myasthenic Disorders 1999, 111-130. Oxford University Press, New York. A. Engel (Ed.).
35. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976, 26:1054-1059.
36. Lobito A.A., Yang B., Lopes M.F., Miagkov A., Adams R.N., Palardy G.R., et al. T cell receptor transgenic mice recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor. Eur. J. Immunol. 2002, 32:2055-2067.
37. McIntosh K.R., Drachman D.B. Tolerance to acetylcholine receptor induced by AChR-coupled syngeneic cells. J. Neuroimmunol. 1992, 38:75-84.
38. McIntosh K.R., Linsley P.S., Bacha P.A., Drachman D.B. Immunotherapy of experimental autoimmune myasthenia gravis: selective effects of CTLA4Ig and synergistic combination with an IL2-diphtheria toxin fusion protein. J. Neuroimmunol. 1998, 87:136-146.
39. Melms A., Malcherek G., Gern U., Wietholter H., Muller C.A., Schoepfer R., et al. T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the alpha-subunit. Ann. Neurol. 1992, 31:311-318.
40. Miagkov A., Turchan J., Nath A., Drachman D.B. Gene transfer of baculoviral p35 by adenoviral vector protects human cerebral neurons from apoptosis. DNA Cell Biol. 2004, 23:496-501.
41. Nair S.K., Boczkowski D., Morse M., Cumming R.I., Lyerly H.K., Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 1998, 16:364-369.
42. Newsom-Davis J., Harcourt G., Sommer N., Beeson D., Willcox N., Rothbard J.B. T-cell reactivity in myasthenia gravis. J. Autoimmun. 1989, 2:101-108. (Suppl.).
43. Ragheb S., Lisak R.P. Immune regulation and myasthenia gravis. Ann. N. Y. Acad. Sci. 1998, 841:210-224.
44. Ramadan G. Generation of functional monocyte-derived fast dendritic cells suitable for clinical application in the absence of interleukin-6. Cytotechnology 2011, 63:513-521.
45. Richman D.P., Antel J.P., Patrick J.W., Arnason B.G. Cellular immunity to acetylcholine receptor in myasthenia gravis: relationship to histocompatibility type and antigenic site. Neurology 1979, 29:291-296.
46. Rigato P., Maciel M., Goldoni A., Piubelli O., deBrito C., Fusaro A., et al. Immunization of neonatal mice with LAMP/p55 HIV gag DNA elicits robust immune responses that last to adulthood. Virology 2010, 406:37-47.
47. Rittenberg M.B., Pratt K.L. Antitrinitrophenyl (TNP) plaque assay. Primary response of Balb/c mice to soluble and particulate immunogen. Proc. Soc. Exp. Biol. Med. 1969, 132:575-581.
48. Rowell J.F., Ruff A.L., Guarnieri F.G., Staveley-O'Carroll K., Lin X., Tang J., et al. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. J. Immunol. 1995, 155:1818-1828.
49. Sanders D., El-Salem K., Irbid J., Massey J., Vincent A. Muscle specific tyrosine kinase (MuSK) positive, seronegative myasthenia gravis (SN-MG). Clinical characteristics and response to therapy. Neurology 2003, Suppl. 1:A418.
50. Schutz C., Oelke M., Schnick J., Mackensen A., Fleck M. Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'. Immunotherapy 2010, 2:539-550.
51. Senju S., Matsunaga Y., Fukushima S., Hirata S., Matsuyoshi H., Nishimura Y. Pluripotent stem cell-derived dendritic cells for immunotherapy. Front. Biosci. 2010, 2:1520-1527.
52. Shelton D., Fujii Y., Knogge W., Lindstrom J. Specific suppression of the antibody response to acetylcholine receptor in vitro and in vivo by daunomycin-acetylcholine receptor conjugates. Ann. N. Y. Acad. Sci. 1988, 540:530-532.
53. Siegel R., Chan F., Chun H., Lenardo M. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 2000, 1:469-474.
54. Snow A., Pandiyan P., Zheng L., Krummey S., Lenardo M. The power and the promise of restimulation-induced cell death in human immune diseases. Immunol. Rev. 2010, 236:68-82.
55. Sterz R.K., Biro G., Rajki K., Filipp G., Peper K. Experimental autoimmune myasthenia gravis: can pretreatment with 125I-labeled receptor prevent functional damage at the neuromuscular junction?. J. Immunol. 1985, 134:841-846.
56. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat. Med. 1998, 4:31-36.
57. Toyka K.V., Drachman D.B., Griffin D.E., Pestronk A., Winkelstein J.A., Fishbeck K.H., et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 1977, 296:125-131.
58. Valentin A., Chikhlikar P., Patel V., Rosati M., Maciel M., Chang K.H., et al. Comparison of DNA vaccines producing HIV-1 Gag and LAMP/Gag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes. Vaccine 2009, 27:4840-4849.
59. Viegas S., Jacobson L., Waters P., Cossins J., Jacob S., Leite M., et al. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp. Neurol. 2012, 234:506-512.
60. Wang Z.Y., Okita D.K., Howard J., Conti-Fine B.M. T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis. Neurology 1998, 50:1045-1054.
61. Watanabe-Fukunaga R., Brannan C., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317.
62. Wraith D.C., McDevitt H.O., Steinman L., Acha-Orbea H. T cell recognition as the target for immune intervention in autoimmune disease. Cell 1989, 57:709-715.
63. Wu B., Goluszko E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Current Protocols in Immunology 1997, vol. 3, Suppl. 21:15.8.1-15.8.18. John Wiley & Sons.
64. Wu B., Wu J.M., Miagkov A., Adams R.N., Levitsky H.I., Drachman D.B. Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy. J. Immunol. 2001, 166:4773-4779.
65. Wu J.M., Wu B., Miagkov A., Adams R.N., Drachman D.B. Specific immunotherapy of experimental myasthenia gravis in vitro: the "guided missile" strategy. Cell. Immunol. 2001, 208:137-147.
66. Yang B., McIntosh K.R., Drachman D.B. How subtle differences in MHC class II affect the severity of experimental myasthenia gravis. Clin. Immunol. Immunopathol. 1998, 86:45-58.
67. Yeh T.M., Krolick K.A. Influence of T cell specificity on the heterogeneity and disease-causing capability of antibody against the acetylcholine receptor. J. Neuroimmunol. 1987, 17:17-34.
68. Zhang H.G., Liu D., Heike Y., Yang P., Wang Z., Wang X., et al. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat. Biotechnol. 1998, 16:1045-1049.